ASH 2018 | CLL news from ASH 2018: ibrutinib strikes again!

Stephan Stilgenbauer

Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, discusses the chronic lymphocytic leukemia (CLL) highlights at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video  
Similar topics
Related videos
3:04
Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery
3:04
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
3:04
An exciting era for CAR T-cell therapy
Mohamad Mohty
3:04
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
3:04
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
Chronic Lymphocytic Leukemia, Leukemia
Bendamustine, Ibrutinib, Obinutuzumab, Rituximab, Venetoclax
ALLIANCE A041202, ECOG-E1912, iLLUMINATE, MURANO
ASH 2018, ASH2018CLL
Interview
More from Stephan Stilgenbauer
DUO results: duvelisib or ofatumumab monotherapy for R/R CLL?
Can we afford to have CLL patients on a therapy for the rest of their lives?
CLL2-GIVe trial: investigating chemotherapy-free treatment of CLL
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals